MeCo Diagnostics, an EvoNexus Portfolio Company, and CNIO Announce Positive Phase II Study Data
MeCo Diagnostics, an EvoNexus Portfolio Company, and CNIO Announce Positive Phase II Study Data SAN DIEGO, CA & MADRID, SPAIN / AUGUST 15TH, 2023 / On August 15th, MeCo Diagnostics […]